Question

I need a clear essay about MAGNOVA COMPONENTS.

INTRODUCTION - 200words

BODY - 400 words

CONCLUSION - 200 words.

please don't copy from old chegg answers.satisfactory answer will be given up-vote.

Answer 1

MAGNOVA COMPONENTS

Ans:

Magnova is cephalosporin antibiotic, prescribed for certain bacterial infections. It kills sensitive bacteria. Magnova may be prescribed for Urinary Tract and infections. It comes as a solution for injection, administered by a healthcare provider either into a large muscle or vein over 30 minutes.

SALT COMPOSITION of Cefepime (1000mg) + Tazobactum (125mg) is Magnova Components. Magnova 1000 mg/125 mg Injection is a combination of two antibiotics. It is prescribed to treat various types of bacterial infections. It fights against the infection by preventing the growth of microorganisms.

Cefepime is an antibiotic. It works by preventing the formation of the bacterial protective covering which is essential for the survival of bacteria in the human body.

Tazobactum is a beta-lactamase inhibitor which blocks the action of enzymes produced by bacteria to inactivate cefepime. Addition of Tazobactum reduces resistance and enhances the activity of Cefepime against bacteria.

Cefepime (Magnova) injection is used to treat bacterial infections in many different parts of the body. It belongs to the class of medicines known as cephalosporin antibiotics. It works by killing bacteria or preventing their growth. However, Cefepime (Magnova) will not work for colds, flu, or other virus infections.

Cefepime (Magnova) Injection is indicated for complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, or Bacteroides fragilis.

Cefepime (Magnova) Injection is indicated for pneumonia (moderate to severe) caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae, or Enterobacter species. Injection is used as monotherapy is indicated for empiric treatment of febrile neutropenic patients. Injection is indicated for uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae. Cefepime (Magnova) Injection is indicated for uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes.

Each 20 mL vial contains either 1.914 g or 3.828 g of sterile Cefepime (Magnova)-L-arginine powder, which is equivalent to 1 g or 2 g of Cefepime (Magnova) and approximately 725 mg of arginine per gram of Cefepime (Magnova). It contains no antimicrobial preservative and is for use in one patient only.

Tazobactam (Magnova) is a antibacterial penicillin derivative which inhibits the action of bacterial beta-lactamases.

Used in combination with piperacillin to broaden the spectrum of piperacillin antibacterial action. (Animal bite; Pelvic inflammatory disease; Peritonitis; complicated Appendicitis; complicated Pyelonephritis; complicated bacterial urinary tract infections; complicated intra-abdominal bacterial infections; moderate Bacterial infection; moderate Community acquired pneumonia; moderate Nosocomial pneumonia; postpartum endometritis; severe Bacterial infection; severe Nosocomial pneumonia; surgical site infection; uncomplicated skin and subcutaneous tissue bacterial infections;

Side effects of SIDE EFFECTS Tazobactam (Magnova) are Liver enzyme increased, Bruise, Bleeding, Constipation, Diarrhoea, Altered taste, Shortness of breath, Flatulence, Headache, Insomnia, Itching, Skin rash, Stomach upset, Vomiting.

Cefipime works by interfering with the bacterial cell wall synthesis. Tazobactam inhibits some of the chemicals produced by the bacteria and makes the bacteria more sensitive to cefipime activity. Thus, their combination becomes effective against an extended range of bacteria.

Magnova 1000 mg/125 mg Injection should only be administered under the supervision of a healthcare professional.

Magnova 1 g + 125 mg Injection is a combination medicine used to treat infections of the lower respiratory tract, urinary tract, blood, intraabdominal infections, skin and soft tissue infections, etc. caused by susceptible bacteria. It is also used as an empirical treatment in patients suffering from febrile neutropenia. This medicine should be used with caution in patients with kidney diseases due to the increased risk of severe adverse effects.

Major & minor side effects for Magnova 1 g + 125 mg Injection is ·Nausea ,Vomiting, Diarrhea, Abdominal pain, Bleeding gums, Fever, Headache, Yellowing of skin and eyes, Swelling of foot, Redness of skin, Pain at the injection site, Sour mouth.

This medicine is not recommended for use in patients with a known allergy to cefipime, any other beta-lactam antibiotics, tazobactam, or any other inactive ingredients present along with these medicines.
Caution should be exercised in patients with history of penicillin or cephalosporin allergy, gastro intestinal disease, especially colitis; lactation, pregnancy, seizures.

• It may decrease prothrombin activity; monitor prothrombin time in patients with poor nutritional state, kidney or liver impairment and those on prolonged treatment.

• Prolonged treatment may result in overgrowth of non-susceptible organisms, resulting in superinfection.

• Consider the possibility of Clostridium difficile associated diarrhea in patients who present with diarrhea after treatment.

•  Patient may develop with increased risk of neurotoxicity.

Other Precautions for Magnova

In diabetes patients - it may cause the results of some tests for urine glucose to be wrong. Becareful while changing the dose of your diabetes medicine.

Pregnancy : This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.

Breast-feeding :This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.

Since this medicine is administered in the hospital or clinical setting by a qualified health-care professional, the likelihood of an overdose or missed dose is very low. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.